Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets
返回论文页
Review article|更新时间:2023-08-29
|
Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets
Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets
Genes & Diseases2023年10卷第3期
作者机构:
Raja Peary Mohan College Integrated Biological Research Facility (RIBRF), Raja Peary Mohan College, Uttarpara, Hooghly, West Bengal,India,712258
Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets[J]. Genes & Diseases, 2023,10(3).
Abhi Dutta, Moumita Das, Ankita Ghosh, et al. Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets[J]. Genes & Diseases, 2023,10(3).
Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets[J]. Genes & Diseases, 2023,10(3). DOI: 10.1016/j.gendis.2022.08.008.
Abhi Dutta, Moumita Das, Ankita Ghosh, et al. Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets[J]. Genes & Diseases, 2023,10(3). DOI: 10.1016/j.gendis.2022.08.008.
Molecular and cellular pathophysiology of circulating cardiomyocyte-specific cell free DNA (cfDNA): Biomarkers of heart failure and potential therapeutic targets
摘要
Abstract
Pathological cardiac damage during heart failure is associated with cell death and damage associated molecular patterns (DAMPs) release which triggers a viscous cycle of sterile inflammation to mediate maladaptive cardiac tissue remodelling during the progression to heart failure. DAMPs like cytokines
chemokines
and nuclear or mitochondrial genomic fragments are released in the pathological myocardium. Interestingly
circulating or cytosolic DNA fragments can play a role in the disease by interaction with nucleic acid sensors expressed in cardiomyocyte and non-myocyte neighbouring cells. The circulating cell free DNA (cfDNA) fragments have been clinically reported as markers for various diseases including cardiovascular pathophysiology. Such cfDNA within the DAMP pool can mediate intra- and inter-cellular signalling cascade to upregulate transcriptional expression of inflammatory mediators and trigger oxidative stress within cells. The cellular role of such genomic equivalents varying with chronic or acute stress might be correlated with the cell death forms encountered in myocardium during disease progression. Thus
cfDNA can be phenotypically correlated as a critical player towards upregulation of pathological processes like interstitial fibrosis
cardiomyocyte contractile dysfunction and cell death. Herein
we review the association of cfDNA with heart failure and analyse their potential usage as novel and effective therapeutic targets towards augmentation of cardiac function.
Hypercalciuria switches Ca2+ signaling in proximal tubular cells, induces oxidative damage to promote calcium nephrolithiasis
The essential role of N6-methyladenosine RNA methylation in complex eye diseases
Long non-coding RNA (lncRNA): A potential therapeutic target in acute lung injury
The journey towards physiology and pathology: Tracing the path of neuregulin 4
Autophagy-related lncRNAs in tumor progression and drug resistance: A double-edged sword
相关作者
Samuel Shin
Cliff-Lawrence Ibeh
Eugenia Awuah Boadi
Bok-Eum Choi
Sanjit K. Roy
Bidhan C. Bandyopadhyay
Xiaohua Li
Binyun Ma
相关机构
Calcium Signaling Laboratory, Research Service, Veterans Affairs Medical Center, 50 Irving Street,,, DC
Department of Ophthalmology, Lanzhou University Second Hospital
Henan Provincial People’s Hospital, Henan Eye Hospital, Henan Eye Institute, Henan Key Laboratory of Ophthalmology and Visual Science, People’s Hospital of Zhengzhou University, People’s Hospital of Henan University
Department of Ophthalmology, Tianjin Medical University General Hospital, Laboratory of Molecular Ophthalmology, Tianjin Medical University. Department of Pharmacology and Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University
Department of Pathology and Ophthalmology, USC Roski Eye Institute, Keck School of Medicine, University of Southern California